Pharmaceutical Companies’ Variation Of Drug Prices Within And Among Countries Can Improve Long-Term Social Well-Being
- 1 August 2011
- journal article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 30 (8) , 1539-1544
Abstract
Drug prices vary considerably across and within countries. On average, pharmaceutical companies charge lower prices in low-income countries than in industrialized nations. Manufacturers’ ability to price products differently for different markets—a practice known as price discrimination—increases their profits overall. But it is also likely to result in greater investment in research and development, and therefore in more new drugs on the market. Although reducing price discrimination in order to cut costs might benefit consumers in the short run, it would harm them in the long run by reducing the number of new drugs developed.Keywords
This publication has 7 references indexed in Scilit:
- IMPORTATION AND INNOVATIONEconomics of Innovation and New Technology, 2007
- The cost of US pharmaceutical price regulation: a financial simulation model of R&D decisionsManagerial and Decision Economics, 2007
- Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS DrugsForum for Health Economics and Policy, 2006
- Drug Prices and Research and Development Investment Behavior in the Pharmaceutical IndustryThe Journal of Law and Economics, 2005
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Market Opening under Third-Degree Price DiscriminationThe Journal of Industrial Economics, 1994
- Price Discrimination and Patent PolicyThe RAND Journal of Economics, 1988